Compare Cassava Sciences Inc (FLNA) vs HubSpot Inc (HUBS) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

HubSpot (HUBS) trades at $233.94, up 6.19% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $3.26, beating estimates of $3.02, continuing a trend of positive surprises. Revenue growth is robust, with 2025 revenue at $3.13 billion, and net income turning positive at $45.91 million. Analyst sentiment remains largely positive with a consensus price target of $243.65, though valuation multiples like a P/E of 82.51 are elevated. Recent news highlights AI strategy advancements and partnerships, including a deepened collaboration with OpenAI.

The outlook for HUBS is cautiously optimistic, driven by strong revenue growth, margin expansion potential, and strategic AI initiatives. Key risks include high valuation multiples, competitive pressures in the CRM space, and potential demand headwinds from economic conditions. Institutional ownership trends show significant interest, such as the California State Teachers Retirement System increasing its stake. The stock presents a growth opportunity but requires monitoring of execution risks and market sentiment shifts.